Impact of endometrial carcinoma histotype on the prognostic value of the TCGA molecular subgroups

[1] Siegel RL(2015)Cancer statistics, 2015 CA Cancer J Clin 65 5-29

[2] Miller KD(2019)TCGA Molecular subgroups in endometrial undifferentiated/dedifferentiated carcinoma Pathol Oncol Res 37 874-881

[3] Jemal A(2013)Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma Am J Surg Pathol 37 1421-1432

[4] Travaglino A(2013)Histotype-genotype correlation in 36 high-grade endometrial carcinomas Am J Surg Pathol 497 67-73

[5] Raffone A(2013)Integrated genomic characterization of endometrial carcinoma Nature 113 299-310

[6] Mascolo M(2015)A clinically applicable molecular-based classification for endometrial cancers Br J Cancer 22 4215-4224

[7] Gilks CB(2016)Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts Clin Cancer Res 123 802-813

[8] Oliva E(2017)Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer Cancer 42 561-568

[9] Soslow RA(2018)Molecular classification of grade 3 endometrioid endometrial cancers identifies distinct prognostic subgroups Am J Surg Pathol 148 174-180

[10] Hoang LN(2018)An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer Gynecol Oncol 29 1180-1188

[1] Siegel RL(2015)Cancer statistics, 2015 CA Cancer J Clin 65 5-29

[2] Miller KD(2019)TCGA Molecular subgroups in endometrial undifferentiated/dedifferentiated carcinoma Pathol Oncol Res 37 874-881

[3] Jemal A(2013)Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma Am J Surg Pathol 37 1421-1432

[4] Travaglino A(2013)Histotype-genotype correlation in 36 high-grade endometrial carcinomas Am J Surg Pathol 497 67-73

[5] Raffone A(2013)Integrated genomic characterization of endometrial carcinoma Nature 113 299-310

[6] Mascolo M(2015)A clinically applicable molecular-based classification for endometrial cancers Br J Cancer 22 4215-4224

[7] Gilks CB(2016)Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts Clin Cancer Res 123 802-813

[8] Oliva E(2017)Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer Cancer 42 561-568

[9] Soslow RA(2018)Molecular classification of grade 3 endometrioid endometrial cancers identifies distinct prognostic subgroups Am J Surg Pathol 148 174-180

[10] Hoang LN(2018)An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer Gynecol Oncol 29 1180-1188